Literature DB >> 17548443

Treatment of depression in people who have multiple sclerosis.

A C Sollom1, I I Kneebone.   

Abstract

Depression is common among people with multiple sclerosis (MS). Research suggests that treatments for depression are effective in this population, though few patients appear to access these treatments. Our objectives were to consider whether persons with MS and significant depressive symptoms, prompted to seek treatment by letter, did so, what professionals they consulted, and the benefits of any treatment obtained. A total of 495 individuals with MS (401 female; 94 male), aged 22-65 years (mean: 45.8 years), were surveyed in three phases at yearly intervals. Significant depressive symptoms were found over the three phases (50-60.2%). Despite a high prevalence of depressive symptoms, few participants sought treatment, even though prompted to do so. Where treatment was sought, general practitioners remained the principal group consulted. Contrary to previous reports of the efficacy of treatment in clinical trials, no strong support for this was found. Future research needs to consider why the majority of people with MS do not seek treatment for depression, and why interventions, which are not clinical trials, seem to lack effectiveness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548443     DOI: 10.1177/1352458507072384

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

1.  Relationship between disease-modifying therapy and depression in multiple sclerosis.

Authors:  Stephen S Kirzinger; Jason Jones; Angela Siegwald; Andrew Bryce Crush
Journal:  Int J MS Care       Date:  2013

2.  Vascular intervention for multiple sclerosis.

Authors:  Michael Kolber; Ken Makus; G Michael Allan; Noah Ivers
Journal:  Can Fam Physician       Date:  2011-06       Impact factor: 3.275

3.  Computerized Cognitive Behavioral Therapy for Treatment of Depression in Multiple Sclerosis: A Narrative Review of Current Findings and Future Directions.

Authors:  Adrianna Ratajska; Jonathan Zurawski; Brian Healy; Bonnie I Glanz
Journal:  Int J MS Care       Date:  2019 May-Jun

4.  Reliability and validity of the Attributional Style Questionnaire- Survey in people with multiple sclerosis.

Authors:  Ian I Kneebone; Sophie J Dewar
Journal:  Ther Adv Neurol Disord       Date:  2016-10-19       Impact factor: 6.570

5.  "Putting one foot in front of the other": a qualitative study of emotional experiences and help-seeking in women with multiple sclerosis.

Authors:  Joanna Blundell Jones; Sue Walsh; Claire Isaac
Journal:  J Clin Psychol Med Settings       Date:  2014-12

Review 6.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.

Authors:  Claudio Solaro; Giulia Gamberini; Fabio Giuseppe Masuccio
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

7.  Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis.

Authors:  Aida Raissi; Andrew G M Bulloch; Kirsten M Fiest; Keltie McDonald; Nathalie Jetté; Scott B Patten
Journal:  Int J MS Care       Date:  2015 Nov-Dec

8.  Computerised cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: external pilot trial.

Authors:  Cindy L Cooper; Daniel Hind; Glenys D Parry; Claire L Isaac; Munyaradzi Dimairo; Alicia O'Cathain; Anita Rose; Jennifer V Freeman; Leonie Martin; Eva C Kaltenthaler; Anna Thake; Basil Sharrack
Journal:  Trials       Date:  2011-12-14       Impact factor: 2.279

9.  The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis.

Authors:  Nicole M Stroud; Clare L Minahan
Journal:  Health Qual Life Outcomes       Date:  2009-07-20       Impact factor: 3.186

10.  Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations.

Authors:  Maria Skokou; Evanthia Soubasi; Philippos Gourzis
Journal:  ISRN Neurol       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.